Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles

Open Access

Original Article

Med Arch. 2018; 72(5): 325-329

Hepatitis C Treatment in Patients with Drug Addiction Is Effective or Not Effective?

Seyed Amineh Hojati, Elham Maserat, Mohammad Ghorbani, Alireza Safarpour, Mohammad Reza Fattehi.

Introduction: Patients with drug addiction have high risk for hepatitis C virus (HCV). Effective treatment response is essential to optimize treatment for drug abusers infected by hepatitis C virus. Aim: The aim of this present study was to show that hepatitis C treatment in patients with drug addiction is effective like patients without drug addiction. Material and Methods: Total amount of 57 patients with hepatitis C (25 drug abuser and 32 non–drug abuser) that referred to Shahid Motahari clinic of Shiraz were selected. All patients infected with HCV treated by combination regimens of ribavirin, sofosbuvir and interferon. Patients received sofosbuvir (400mg once a day) in combination with peg-IFN-alpha (92a180m/w›92b1/5m/kg/w) and RBV (under 75 kg 1000mg, over 75 kg 12000kg) for 12 weeks. The Kolmogorov–Smirnov test was used for testing normality. Associations between variables were analyzed using a Chi-square, Fisher exact, T student and Mann–Whitney U test. Results: Out of 25 HCV patients (43.9%) were drug addicts and 32 patients (56.1%) were non-drug addicts. Insomnia (61.4%), fatigue (63.1%) and debility (49.1%) were more common adverse effects of therapy in drug abusers and non-drug abusers. Alanine transaminase (ALT) and HCV RNA was normal in the end of therapy (EOT). White blood cell (WBC) count decreased in during two-week after starting of the treatment and then increased to normal levels at the end of treatment. Reduction of WBC count was considerable in during two-week. Hematologic result was not considerable. Reduction of hemoglobin was

Key words: Hepatitis C virus, Drug Addiction, Treatment.

Similar Articles

Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease.
Goulding SR, Anantha J, Collins LM, Sullivan AM, O'Keeffe GW
Neural regeneration research. 2022; 17(1): 38-44

Boosting proteolytic pathways as a treatment against glycation-derived damage in the brain?
Taylor A, Bejarano E
Neural regeneration research. 2022; 17(2): 320-322

Exosome treatment for stroke with diabetic comorbidity.
Venkat P, Chopp M
Neural regeneration research. 2022; 17(2): 315-317

Delving into the recent advancements of spinal cord injury treatment: a review of recent progress.
Flack JA, Sharma KD, Xie JY
Neural regeneration research. 2022; 17(2): 283-291

Distribution of antibiotic resistance genes and their association with bacteria and viruses in decentralized sewage treatment facilities.
Zhao J, Li B, Lv P, Hou J, Qiu Y, Huang X
Frontiers of environmental science & engineering. 2022; 16(3): 35

Full-text options

Add your Article(s) to Indexes
• citeindex.org

Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.